PAIN MANAGEMENT AND ADDICTION

NEWSLETTER

AND MINUTES OF THE ANNUAL MEETING

SEPTEMBER 2024



Section Meeting


The Pain Management and Addiction Section Meeting was called to order at 1 pm September 29, 2024 in the Mandalay Bay Hotel, Las Vegas by Dr. Reuben Strayer, MD, FACEP, Chair and Councilor for the section.


Dr. Rami R. Khoury, MD, FACEP Board Liaison to the Section gave an in depth slide presentation about all the Activities of the College over the past year.

Dr. Strayer gave a report on the Council Meeting as it pertains to our section. The Council seems quite receptive to our issues.











2023-2024 Officers

Chair: Dr. Reuben Strayer emupdates@gmail.com
Chair-Elect: Dr. Rachel Haroz rachelharoz@gmail.com
Past-Chair: Dr. Don Stader edonald.stader@gmail.com
Newsletter Editor: Dr. John Bibb jdbibb@aol.com
Board Liaison: Dr. Rami Khoury rkhoury@acep.org

HIGHLIGHTS OF THE MEETING

Innovation and Excellence in Behavioral Health and Addiction Medicine Award

The Innovation and Excellence in Behavioral Health and Addiction Medicine Award went to Dr. Aimee K Moulin, MD, FACEP. Dr. Moulin has been a multifaceted leader in addiction medicine and behavioral health and emergency medicine in general. Most spectacularly she was instrumental in passing legislation that initiated The California Bridge Program. There is funding form the California State Legislature that has allowed for 140,000 buprenorphine starts in California. Dr. Moulin explains her legislative success as follows: "I show up and I just don't go away."



The landscape of pain management is evolving, with regional anesthesia and emerging techniques like cryoneurolysis offering innovative solutions for a variety of painful conditions. This is true especially for patients with substance us disorders. Dr. Katherine Vlasica and Dr. Christine Collins discussed the evolving innovative indications for regional anesthesia in pain management.





HIGHLIGHTS OF THE MEETING

Injectable Extended Release Buprenorphine-Dr. Gail D'Onofrio



Dr. Gail D'Onofrio, MD, MS, FACEP, presented on the 7-day parenteral extended-release buprenorphine. This administration method results in a slower rise in blood levels and can be administered at lower Clinical Opiate Withdrawal Scale (COWS) scores of 4-7. Precipitated withdrawal occurred in only about 7 out of 100 patients. The 7-day dose can effectively bridge patients from the emergency department to their first clinic visit.


Addiction-trained Emergency Physicians: Where To Go From Here? - Dr. Rachel Haroz



Dr. Rachel Haroz, MD, Chair-elect, led a discussion on the challenges emergency physicians face in practicing addiction medicine and establishing dedicated services within hospitals. Financial constraints were a key concern. Participants emphasized the importance of presenting a financial plan to leadership that demonstrates how addiction medicine can be cost-effective. For instance, initiating buprenorphine for patients can significantly reduce repeat emergency department visits and hospital admissions.

A PERSONAL NOTE FROM THE EDITORS OF THE NEWSLETTER:

We take immense pride in the dedication of emergency physicians committed to assisting those with substance use disorders, and who are actively working to mitigate addiction risk by creating pain management initiatives. Substance use has long been a challenge for both patients and physicians, and the current rise in mortality rates amplifies the urgency of addressing it. This section is now intensifying efforts to proactively address this. Kudos for the unwavering commitment to delivering exceptional care to all patients, with a special emphasis on the most vulnerable population of patients with substance use disorder.



JOHN BIBB, MD, FACEP



CHRISTINE COLLINS, MD